DEB & cTACE in Primary and Secondary Liver Cancer, Villejuif (FR), December 13-14, 2018
HCC is a common type of cancer with increasing incidence. Intra-arterial therapies are often part of the treatment algorithm and several intra-arterial treatment options are available today, including C-TACE, DEB-TACE, balloon TACE and TARE. This Clinical Procedure Training course gives experienced physicians the opportunity to fine-tune their practical skills and learn more about current treatment options for various stages of HCC and liver metastatic disease.
Theoretical presentations will be organised to allow participants to understand the staging and treatment algorithm of HCC and metastatic liver disease. Hands-on sessions will then provide the opportunity to handle current devices and to learn about the most advanced technologies fit for intra-arterial therapy. Due to the complexity of treating HCC and liver metastases, collaboration between medical oncologists, surgeons and radiation therapists is needed. A section of the programme will be dedicated to imaging follow-up and treatment evaluation. Highly experienced physicians will present complications and lessons learned.
We hope you can join us at the prestigious Gustave Roussy Cancer Centre, located near Paris, for this exciting course!
Thursday, December 13, 2018
|TACE for HCC|
|Lecture 1||HCC overview of staging systems (BCLC, HKLC, others)|
|Lecture 2||TACE in HCC: Patient selection to maximise outcomes and avoid|
|Lecture 3||TACE HCC: Rationale to combine with systemic therapies, results|
|and possible future development|
|Lecture 4||Is there any indication for TACE in advanced HCC patients?|
|TACE for Liver Metastases|
|Lecture 5||TACE for NET: Patient selection, treatment outcomes and|
|Lecture 6||DEB-TACE for other metastases (colorectal, breast, ...): Patient|
|selection, technical points, treatment schedule and follow-up,|
|Lecture 7||Conventional TACE is better|
|Lecture 8||Drug eluting microspheres TACE is better|
|TACE in Clinical Practice|
|Lecture 9||TACE for HCC in clinical practice: Treatment schedule, clinical and|
|biological follow-up. When to stop? When to retreat?|
|Lecture 10||How to evaluate response to TACE: RECIST, mRECIST, rRECIST,|
|Lectures 11-15||TACE: Lesson learned from the worst complication I ever had|
|Lecture 16||TACE + Ablation: For whom, when, and how?|
|Lecture 17||Balloon TACE: A new kid on the block|
|Lecture 18||TACE or TARE: An honest appraisal, how to select patient and|
|The future of TACE|
|Lecture 19||New drugs: Sunitinib? Vandetanib?|
|Lecture 20||New drugs: Idarubicin?|
|Lecture 21||Drugs are old fashioned: Suicide genes|
Friday, December 14, 2018
|Live case #1: C-TACE|
|Live case #2: DEB-TACE|
|Certificate of attendance|
T. de Baère, Villejuif (FR)
I. Bargellini, Pisa (IT)
T. de Baère, Villejuif (FR)
A. Denys, Lausanne (CH)
F. Deschamps, Villejuif (FR)
B. Guiu, Montferrier sur Lez (FR)
T. Jakobs, Munich (DE)
O. Pellerin, Paris (FR)
M. Ronot, Clichy (FR)
L. Tselikas, Villejuif (FR)
Institut Gustave Roussy
Early Registration Fees (until October 18):
Course Registration - Single €550
Course Registration - Team** €800
CIRSE Member - Single €350
CIRSE Member - Team** €500
Nurse/Radiographer Non-Member* €280
Nurse/Radiographer Member* €210
Late Registration Fees (from October 19):
Course Registration - Single €700
Course Registration - Team** €1100
CIRSE Member - Single €450
CIRSE Member - Team** €700
Nurse/Radiographer Non-Member* €380
Nurse/Radiographer Member* €310
Please note that the ESIR course in Villejuif is limited to 44 participants.
* Registration needs to be accompanied by the Confirmation Form, signed by the head of department.
** Upon approval, (interventional) radiologists attending the course may bring with them a colleague from the same hospital but a different medical specialty, with whom they work together in a multidiscplinary team which is relevant for the treatment of the patient. These two physicians will then be able to attend the ESIR course under the "Team Fee". Just choose the "Team Fee" and contact email@example.com with details regarding your non-IR colleague.
Please note that the following are only suggestions. Accommodation is not included in the registration fee of ESIR courses. CIRSE supports compliance with ethical standards. Therefore, CIRSE emphasises that the participants shall bear any and all costs in this context themselves.
Paris Marriott Rive Gauche Hotel:
17 Boulevard Saint Jacques
Phone: +33 1 40 78 79 80
Fax: +33 1 45 88 43 93
citizenM Paris Gare de Lyon:
8 Rue van Gogh
Phone: +33 1 86 65 07 40
Mercure Paris Notre Dame Saint Germain des Prés:
20 Rue Sommerard
Phone: +33 1 43 54 47 60
Fax: +33 1 43 26 42 34
The ESIR 2018: DEB & cTACE in Primary and Secondary Liver Cancer, Villejuif, France, 13/12/2018-14/12/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Should you have any questions regarding the ESIR course on DEB & cTACE in Primary and Secondary Liver Cancer, please contact us at firstname.lastname@example.org.